0 items
Your cart is empty.
If you are looking to buy Retevmo or order precision oncology medication online from a verified Canadian supplier, Elivena provides authenticated access to targeted cancer therapies with full product traceability and specialist account support. This category focuses on molecularly targeted agents designed to act on the specific genetic alteration driving a patient’s tumour — including Retevmo (selpercatinib), the standard of care for RET-altered lung and thyroid cancers.
Elivena makes it straightforward to order Retevmo 40 mg online with verified product authenticity and specialist-grade supply chain standards.
The shift from non-targeted chemotherapy to precision targeted therapy has transformed outcomes in multiple cancer types. For patients with actionable alterations, targeted agents like Retevmo deliver response rates and durations of response that non-targeted therapy cannot approach. The quality-of-life advantages are equally meaningful: oral administration at home, more predictable tolerability, and the ability to continue treatment over months or years without the cumulative toxicity burden of chemotherapy.
Retevmo’s clinical data sets it apart from anything previously available for RET-altered cancers. In the LIBRETTO-001 trial, treatment-naive patients with RET fusion-positive NSCLC achieved an objective response rate of 84% — compared to approximately 25–35% with standard chemotherapy in the same setting. Median duration of response exceeded 20 months. For RET-mutant medullary thyroid cancer, response rates of approximately 69–73% were achieved across both treatment-naive and previously treated patients. These results establish Retevmo as the standard of care for its approved indications.
Brain metastases are a common and historically difficult complication in RET-driven lung and thyroid cancers. Retevmo’s ability to cross the blood-brain barrier — and its demonstrated intracranial response rates in patients with CNS involvement — represents one of its most clinically important advantages over earlier multikinase inhibitors, which lacked meaningful CNS activity. For patients with brain metastases, Retevmo provides whole-body and intracranial control in a single oral agent.
Earlier agents used in RET-altered cancers — cabozantinib and vandetanib — inhibited RET but also blocked VEGFR2 and many other kinases, producing significant off-target toxicities including severe hypertension, hand-foot syndrome, and gastrointestinal complications. Selpercatinib was engineered specifically for RET, sparing those kinases and delivering a more manageable tolerability profile. For patients, this translates to a treatment they can sustain over the long term.
Precision oncology requires the right agent for the right alteration. When you buy Retevmo or order oncology medication through Elivena, you access the most evidence-backed options available for RET-driven cancers.
Retevmo (Selpercatinib)
The first highly selective oral RET kinase inhibitor. Demonstrated objective response rates exceeding 84% in treatment-naive RET fusion-positive NSCLC in the LIBRETTO-001 trial. Active against brain metastases. Available in 40 mg and 80 mg capsule strengths with weight-based dosing.
Dasatinib
A BCR-ABL tyrosine kinase inhibitor with established use in CML and Philadelphia chromosome-positive ALL. Also being studied for senolytic applications. See Dasatinib.
Other oncology-relevant products available through Elivena include:
Retevmo (selpercatinib) is an oral, first-in-class selective RET kinase inhibitor approved for the treatment of cancers harbouring RET gene alterations. It is indicated for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), advanced or metastatic RET-mutant medullary thyroid cancer (MTC), and advanced or metastatic RET fusion-positive thyroid cancer that is radioactive iodine-refractory. Treatment requires prior confirmation of a RET alteration using an approved companion diagnostic.
Retevmo is available at Elivena in two weight-based capsule strengths: Retevmo 40 mg for patients weighing less than 50 kg, and Retevmo 80 mg for patients weighing 50 kg or more. Both are supplied from licensed Canadian pharmacies with verified product authenticity.
Targeted oncology therapy works by identifying and blocking specific molecular alterations that drive tumour growth — rather than attacking all rapidly dividing cells indiscriminately the way chemotherapy does. When a patient’s cancer carries a known, actionable alteration such as a RET fusion or activating RET mutation, a targeted agent can be prescribed to block exactly that signal, delivering focused antitumour activity while largely sparing healthy tissue.
This precision approach requires molecular profiling — testing of tumour tissue or, increasingly, circulating tumour DNA from a liquid biopsy — to identify the specific genetic change driving the cancer. Different alterations have different drugs. The RET pathway, targeted by Retevmo, is one of the most actionable in current oncology, with some of the highest clinical response rates of any approved targeted therapy.
RET Gene Alterations and Cancer Biology
The RET gene encodes a receptor tyrosine kinase — a protein on the cell surface that receives growth signals from outside the cell and relays them into the nucleus to drive cell division. In normal tissue, RET activation is tightly regulated. In RET-altered cancers, this regulation breaks down entirely.
RET alterations occur in two forms. RET fusions arise when a chromosomal rearrangement joins part of the RET gene to another gene, producing a hybrid protein that is constitutively active — permanently switched on. RET activating mutations are point changes within the RET gene itself that lock the kinase domain in an always-on state. Both drive uncontrolled tumour cell proliferation through the same downstream pathway. RET fusions are found in approximately 1–2% of NSCLC cases and in a subset of thyroid cancers. RET mutations are the primary driver in virtually all hereditary medullary thyroid cancers and the majority of sporadic MTC cases.
